Antibodies
26 February 2016
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis25 February 2016
Seattle Genetics Initiates Phase 1 Trial of SGN-CD19B for Patients with B-cell Non-Hodgkin Lymphoma25 February 2016
LeafBio Announces Conclusion of ZMapp™ Clinical Trial23 February 2016
Formycon and bioeq enroll first patient in pivotal phase III study with biosimilar ranibizumab (FYB201)22 February 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis17 February 2016
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis17 February 2016
Durvalumab granted Breakthrough Therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer15 February 2016
JHL Biotech Receives Approval From European Authorities to Begin Biosimilar Clinical Trial9 February 2016
EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)9 February 2016
ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-301 in Acute Myeloid Leukemia9 February 2016
ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-301 Trial in Acute Myeloid Leukemia8 February 2016
PlantForm Corporation awarded Government of Canada contract for plant-based production of anti-ricin antibody8 February 2016
OncoMed Provides Update on Tarextumab Phase 2 Programs4 February 2016
Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Taked3 February 2016
Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD473 February 2016
ImmuNext’s anti-VISTA Antibody Enters the Clinic for Cancer3 February 2016
Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association1 February 2016
Lpath Completes Dosing in the Lpathomab Phase 1 Safety StudyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports